Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.35
-$0.44-55.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.48% | 18.34% | -7.74% | 13.39% | 6.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.37% | -52.38% | -25.30% | -17.47% | -34.67% |
| Operating Income | 43.37% | 52.38% | 25.30% | 17.47% | 34.67% |
| Income Before Tax | 46.20% | 52.09% | 23.01% | 13.45% | 33.17% |
| Income Tax Expenses | -38.30% | -- | 8.11% | -29.73% | 202.17% |
| Earnings from Continuing Operations | 46.20% | 52.06% | 22.98% | 13.46% | 33.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.20% | 52.06% | 22.98% | 13.46% | 33.09% |
| EBIT | 43.37% | 52.38% | 25.30% | 17.47% | 34.67% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 81.55% | 77.70% | 52.79% | 46.83% | 55.29% |
| Normalized Basic EPS | 81.55% | 77.72% | 52.81% | 46.82% | 55.35% |
| EPS Diluted | 81.55% | 77.70% | 52.79% | 46.83% | 55.29% |
| Normalized Diluted EPS | 81.55% | 77.72% | 52.81% | 46.82% | 55.35% |
| Average Basic Shares Outstanding | 191.54% | 115.02% | 63.14% | 62.75% | 49.66% |
| Average Diluted Shares Outstanding | 191.54% | 115.02% | 63.14% | 62.75% | 49.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |